A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Persistent or recurrent disease ≤ 24 months of last BCG dose, but not classified as BCG unresponsive
Histologically confirmed persistent or recurrent high-risk non-muscle-invasive urothelial carcinoma (UC)
Treated with at least 1 adequate course of induction BCG therapy (at least 5 out of 6 doses)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
You may not be if
Previous or concurrent muscle invasive, locally advanced, or disseminated/metastatic UC
UC in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment
UC and/or CIS in the prostatic urethra within 12 months of enrollment
Clareo Health | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
